Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: OTC US
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Large Pharma

Astellas Pharma Inc

+ Add to Watchlist

ALPMY:US

16.3750 USD 0.2950 1.77%

As of 20:10:01 ET on 03/31/2015.

Snapshot for Astellas Pharma Inc (ALPMY)

Open: 16.2600 Day's Range: 16.2600 - 16.4300 Volume: 20,576
Previous Close: 16.6700 52wk Range: 10.6297 - 16.9900 1-Yr Rtn: +41.24%

Stock Chart for ALPMY

No chart data available.
  • ALPMY:US 16.3750
  • 1D
  • 1M
  • 1Y
16.6700
Interactive ALPMY Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ALPMY

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. SPX -
Earnings Per Share (ttm) -
Est. EPS -
Est. PEG Ratio -
Market Cap (M USD) 37,004.60
Shares Outstanding (M) 2,259.82
30 Day Average Volume 33,607
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield 1.45%
Cash Dividend (USD) -
Dividend Ex-Date 03/26/2015
5 Year Dividend Growth -18.45%
Next Earnings Announcement 05/11/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ALPMY

  • Revenue
  • Net Income (M/JPY)
  • Profit Margin (%)

Company Profile & Key Executives for ALPMY

Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fields of Urology, Immunology including Transplantation and Infectious Diseases, Oncology, Neuroscience and DM Complications and Metabolic Diseases. With over 17,000 global employees, Astellas researches, develops, manufactures, and promotes its prescription drugs through subsidiaries in the US, Europe, and Asia

Masafumi NogimoriChairmanYoshihiko HatanakaPresident/CEO
Yoshiro MiyokawaExecutive Vice PresidentMasao YoshidaSenior Executive Officer
More Company Profile & Key Executives for ALPMY

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil